Bringing
Innovation

To Glaucoma Care


Dedicated to preserving vision in patients with glaucoma1-3

Aiming to advance the future of glaucoma care with the Calibreye Titratable Glaucoma Therapy™ (TGT) Surgical System’s control through unprecedented adjustable outflow

Targeting an unmet need

Every patient with glaucoma is unique, and their surgical options should be adaptable to meet their individual treatment needs over time.3,4 Conventional therapies such as trabeculectomy and tube shunts, while effective, may place patients at an increased risk for complications.5,6 That’s why Myra Vision is focusing on bringing you the Calibreye TGT System.

Adjustable outflow as a patient’s individual treatment needs change

Developed to provide personalized therapy while minimizing complications

Implanted via well-established ab externo delivery

Utilizes materials with a long history of safely being used in the eye for glaucoma treatment

The Calibreye TGT System is for investigational use only and is not for sale in the US or outside the US. Myra, Myra Vision, the Myra logo, and all product and service names on this site are trademarks of Myra Vision Inc., unless otherwise noted.
No use is permitted without prior written authorization.

Designed to offer a safe solution to control IOP7

The innovative Calibreye TGT System is engineered to put outflow control in the hands of ophthalmologists who care for patients with glaucoma and give them the opportunity to provide personalized therapy while minimizing complications.

The Calibreye Shunt’s 4 settings allow for titratable outflow.

The Calibreye TGT System is for investigational use only and is not for sale in the US or outside the US. Myra, Myra Vision, the Myra logo, and all product and service names on this site are trademarks of Myra Vision Inc., unless otherwise noted.
No use is permitted without prior written authorization.

The Calibreye TGT System is for investigational use only and is not for sale in the US or outside the US. Myra, Myra Vision, the Myra logo, and all product and service names on this site are trademarks of Myra Vision Inc., unless otherwise noted. No use is permitted without prior written authorization.

View Implantation

View TITRATION

Low-profile design and material properties of the Calibreye Shunt are believed to assist with conforming to the shape of the eye1

  • 10.0 x 1.6–mm overall dimensions intended to provide posterior bleb formation to increase aqueous drainage
  • Low profile (0.30 mm thick) to help maximize patient comfort and minimize erosion risk
  • Suture eyelets for a secure shunt placement
  • Visual indication for confirmation of channel settings
  • Silicone
    • Hydrophobic properties help reduce protein binding to minimize cellular adhesion​10
    • Flexible and stable polymer with minimal biodegradation in vivo11
    • Hyperemia is milder than with stainless steel11
    • Inflammatory response is milder than with polypropylene used in other devices11
  • Valve components composed of nitinol, a material with a proven history of use in ocular applications4

About Myra Vision

Myra Vision is a dynamic organization committed to bringing personalized glaucoma care to the surgical armamentarium by delivering an adjustable solution for patients who are candidates for filtration surgery.

Shifamed is a medical technology innovation hub, at the forefront of the medtech industry since 2007, addressing critical healthcare challenges through technology and collaboration.

With the continuing support of Shifamed, Myra Vision, a standalone company, is dedicated to bridging the gap between art and science to help preserve vision for patients with glaucoma requiring low IOP.

References: 1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440. 2. Leske MC, Heijl A, Hyman L, et al; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965-1972. 3. Jayaram H. Intraocular pressure reduction in glaucoma: does every mmHg count? Taiwan J Ophthalmol. 2020;10(4):255-258. 4. Harasymowycz P, Birt C, Gooi P, et al. Medical management of glaucoma in the 21st century from a Canadian perspective. J Ophthalmol. 2016;6509809. 5. Cursiefen C, Cordeiro F, Cunha-Vaz J, Wheeler-Schilling T, Scholl HPN; EVI Steering Board. Unmet needs in ophthalmology: a European Vision Institute-consensus roadmap 2019-2025. Ophthalmic Res. 2019;62(3):123-133. 6. Sheybani A, Scott R, Samuelson TW, et al. Open-angle glaucoma: burden of illness, current therapies, and the management of nocturnal IOP variation. Ophthalmol Ther. 2020;9(1):1-14. 7. Data on file. Myra Vision; 2023. 8. Lim KS, Allan BD, Lloyd AW, Muir A, Khaw PT. Glaucoma drainage devices; past, present, and future. Br J Ophthalmol. 1998;82(9):1083-1089. 9. Samet S, Ong JA, Ahmed IIK. Hydrus microstent implantation for surgical management of glaucoma: a review of design, efficacy and safety. Eye Vis (Lond). 2019;6:32. 10. Windhövel C, Harder L, Bach JP, et al. Comparison of six different silicones in vitro for application as glaucoma drainage device. Materials (Basel). 2018;11(3):341. 11. Nakamura K, Fujimoto T, Okada M, et al. Tissue reactivity to, and stability of, glaucoma drainage device materials placed under rabbit conjunctiva. Transl Vis Sci Technol. 2022;11(4):9.

Thank you for SIGNING UP to receive updates from Myra Vision.

You are now leaving this website

If you would like to navigate away from this website, please select Continue.
To resume exploring the website, please click Stay on This Site.